PD-L2 ELISA Kit, Human

Hakarel

Catalog No.: HAK-HELPDL2-1

Background and Measurement Principal

Immune checkpoint blockade therapies targeting programmed cell death protein 1 (PD-1) achieve marked clinical benefits in cancer patients harboring programmed death ligand-1 (PD-L1) expression tumors. PD-L2 was confirmed highly expressed in HNSCC, salivary gland cancer (SGC), prostate cancer, gastric cancer, colorectal cancer, oesophageal adenocarcinoma, and bladder cancer. Although the structure of PD-L2 is similar to PD-L1, the binding affinity between PD-L2 and PD-1 is two- to sixfold higher than that with PD-L1, suggesting PD-L2 is an important molecule in immune escape as the strong interaction inhibits cytokines secretion and proliferation of T cells. These findings open a new era to understand the function of PD-L2 and provide new insights for improving the efficiency of anti-PD-1 therapy. 1)
This kit detects human PD-L2 by a two-step sandwich method using the high-performance antibody against human PD-L2, an immune checkpoint related molecule.

Features

• Directly quantitate PD-L2 in the cell culture supernatant.
• No special equipment is required. Standard microplate reader capable of reading at 450nm
  will do the job.
• Detects high sensitivity human PD-L2 with rapidly by a two-step sandwich method
  using solid phase anti human PD-L2 antibody and HRP conjugated anti human PD-L2
  antibody.

Please Note: This product is manufactured upon receipt of order. Delivery time is 3 to 4 weeks.